← Back to Search

Virus Therapy

VM-202 for Diabetic Neuropathy

Phase 2
Waitlist Available
Led By Christine N. Sang, MD, MPH
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 90, day 180, day 270, day 365
Awards & highlights

Summary

This trial is testing a new drug to see if it is safe and effective in treating people with a specific type of nerve pain.

Eligible Conditions
  • Diabetic Neuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 90, day 180, day 270, day 365
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 90, day 180, day 270, day 365 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Morphine
Secondary study objectives
Efficacy- Change in Average Pain Intensity
Opioid use - mean dose
Opioid use - percent change from baseline
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: VM-202Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,653 Previous Clinical Trials
11,490,985 Total Patients Enrolled
Christine N. Sang, MD, MPHPrincipal InvestigatorBrigham and Women's Hospital
2 Previous Clinical Trials
52 Total Patients Enrolled
~9 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top